| NCT06127043 | A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA) | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-12-04 | 2026-05 | 2026-01 |
| NCT06041269 | A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR) | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-08-31 | 2025-05-30 | 2024-11-29 |
| NCT05935085 | This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD). | TERMINATED | PHASE2 | 2023-06-13 | 2025-01-07 | 2024-10-16 |
| NCT05205070 | A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata | UNKNOWN | PHASE2 | 2021-12-22 | 2023-03-19 | 2023-01-19 |
| NCT03614923 | Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | COMPLETED | PHASE2 | 2018-11-29 | 2020-10-26 | 2020-09-02 |
| NCT03533751 | Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis | COMPLETED | PHASE2 | 2018-06-19 | 2019-12-03 | 2019-12-03 |
| NCT03469934 | Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma | COMPLETED | PHASE2 | 2017-11-14 | 2018-10-30 | 2018-10-30 |
| NCT02920021 | Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy | COMPLETED | PHASE2 | 2017-01-26 | 2018-03-30 | 2018-03-30 |